VIRAMUNE TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

NEVIRAPINE

থেকে পাওয়া:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

এটিসি কোড:

J05AG01

INN (আন্তর্জাতিক নাম):

NEVIRAPINE

ডোজ:

200MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

NEVIRAPINE 200MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

60

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0134602001; AHFS:

অনুমোদন অবস্থা:

CANCELLED POST MARKET

অনুমোদন তারিখ:

2019-05-24

পণ্য বৈশিষ্ট্য

_ _
_VIRAMUNE Product Monograph_
_ _
_Page 1 of 62_
PRODUCT MONOGRAPH
Pr
VIRAMUNE®
(NEVIRAPINE)
IMMEDIATE-RELEASE TABLETS
200 MG
Pr
VIRAMUNE® XR
(NEVIRAPINE)
EXTENDED-RELEASE TABLETS
400 MG
ANTIRETROVIRAL AGENT
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
WITH ACTIVITY AGAINST
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)
BOEHRINGER INGELHEIM (CANADA) LTD.
5180 SOUTH SERVICE ROAD
BURLINGTON, ONTARIO
L7L 5H4
DATE OF REVISION:
NOVEMBER 18, 2013
CONTROL NUMBER: 167894
For BICL use only: Tracking CCDS # 0199-17
_ _
_VIRAMUNE Product Monograph_
_ _
_Page 2 of 62_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................21
DOSAGE AND ADMINISTRATION
..............................................................................34
OVERDOSAGE
................................................................................................................36
ACTION AND CLINICAL PHARMACOLOGY
............................................................36
STORAGE AND STABILITY
..........................................................................................39
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................39
PART II: SCIENTIFIC INFORMATION
...............................................................................41
PHARMACEUTICAL INFORMATION
..............